Introducing Dimension Bio

A New Name for a Bolder Future

Five years ago, Dimension Inx embarked on a bold idea: What if we could unite biology and engineering—to reimagine how biomaterials could truly change the way we treat patients?

From our earliest pitch decks, we imagined therapies that could restore or even replace lost organ function—life-changing solutions for patients facing disease, trauma, or aging.

Early R&D confirmed the promise. Our biomaterial scaffolds uniquely demonstrated rapid vascularization, resistance to foreign body response, and a natural affinity for cells. It was a breakthrough, but also a signal: we could go further.

By 2022, what began as exploration became intentional. Our data strengthened. The platform evolved and matured into BioNidum™, our bioinspired delivery system that transforms cells into implantable, tissue-like therapies, i.e., tissue therapeutics. We explored ovarian cells to treat infertility and quickly advanced to islet cells for diabetes. This work revealed the potential for first-in-class impact in areas of urgent medical need. With insight from our board, advisors, and partners, we turned our focus to liver disease—a field in desperate need of innovation.

Backed by a strong foundation—an FDA-cleared biomaterial and a fully established GMP manufacturing process—we moved fast. Within a year, we had compelling preclinical data and a clear path to the clinic with our tissue therapeutic for liver failure.

Now, we’re doubling down on our founding vision: to reimagine what’s possible in regenerative medicine.

That vision deserves a name that reflects where we’re going.

Dimension Bio represents not just what we’ve built—but everything that lies ahead. The platform, the passion, the purpose—they remain the same. But the scale? It’s bigger than ever.

We’re just getting started—and we can’t wait to show you what’s next.